CJC-1295 vs Tesamorelin
CJC-1295 is mainly studied for body composition, recovery, gh signaling. while Tesamorelin is studied for visceral fat, body composition. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| CJC-1295 | Tesamorelin | |
|---|---|---|
| Category | Hormonal/Sexual | Metabolic |
| Studied for | Body composition, recovery, GH signaling. | Visceral fat, body composition. |
| How it acts | A synthetic GHRH analog that stimulates the pituitary to release the body's own growth hormone and, by binding to albumin in the blood, keeps acting… | A GHRH analog that stimulates the pituitary to release growth hormone in pulses and is associated with visceral-fat reduction in clinical studies. |
| Evidence level | Limited human evidence | Human trials available |
How they differ
Although sometimes mentioned together, CJC-1295 and Tesamorelin do not target the same thing. CJC-1295: A synthetic GHRH analog that stimulates the pituitary to release the body's own growth hormone and, by binding to albumin in the blood, keeps acting for several days. Tesamorelin: A GHRH analog that stimulates the pituitary to release growth hormone in pulses and is associated with visceral-fat reduction in clinical studies.
See full entry: CJC-1295 → · See full entry: Tesamorelin →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between CJC-1295 and Tesamorelin?
CJC-1295 targets body composition, recovery, gh signaling. and Tesamorelin targets visceral fat, body composition. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, Tesamorelin has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for CJC-1295 vs Tesamorelin or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultshuman J Clin Endocrinol Metab · 2006 · PMID 16352683 →
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analoghuman J Clin Endocrinol Metab · 2006 · PMID 17018654 →
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mousepreclinical Am J Physiol Endocrinol Metab · 2006 · PMID 16822960 →
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potionsreview Subst Use Misuse · 2016 · PMID 26771670 →
- Metabolic effects of a growth hormone-releasing factor in patients with HIVhuman N Engl J Med · 2007 · PMID 18057338 →
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionhuman J Acquir Immune Defic Syndr · 2010 · PMID 20101189 →
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data J Clin Endocrinol Metab · 2010 · PMID 20554713 →
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulationhuman AIDS · 2008 · PMID 18690162 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.